Intestinal ischemia/reperfusion (I/R) injury is a relatively common pathological condition that can lead to multi-organ failure and mortality. Regulatory mechanism for this disease is poorly understood, although it is established that circulating pathogenic natural IgM, which is primarily produced by B1a cells outside of the peritoneal cavity, are integrally involved.
Many inflammatory cytokines contribute to the breach of the gut epithelial barrier during intestinal I/R-induced injury. Among them, IL-6 locally produced in the intestine has been identified as a key inflammatory cytokine that plays an essential role in damaging the tissue during intestinal I/R. In support of this, it has been demonstrated that 1) both in humans (4) and in mice (5, 6) , local levels of IL-6 in the intestine are markedly elevated in association with severe tissue damage after intestinal I/R; 2) IL-6 Ϫ/Ϫ mice developed significantly attenuated intestinal damage after I/R; and 3) blocking IL-6 activity in WT mice using anti-IL-6 mAbs greatly retained intestinal tract integrity after I/R (7) .
Natural IgM has been found to be critical in the pathogenesis of intestinal I/R. These natural antibodies recognize antigens exposed on hypoxic cells after intestinal ischemia and activate complement through the lectin pathway to produce C5a, which can facilitate neutrophil and monocyte infiltration and inflammatory cytokine (e.g. IL-6) production (8, 9) . The first evidence indicating that natural IgM initiates the inflammatory processes to induce intestinal I/R-induced injury was found in studies using the immunodeficient RAG Ϫ/Ϫ mice, which do not have any antibodies (10) . These mice are highly resistant to intestinal I/R-induced injury in association with significantly reduced IL-6 production but become susceptible again after reconstitution with purified serum IgM from naïve WT mice, highlighting the critical role of natural IgM in the development of intestinal I/R-induced injury (10 -14) . Additionally, recent studies have demonstrated the initiation of intestinal I/R-induced injury is not an inherent property of all natural IgM but a subset of natural IgM termed pathogenic natural IgMs (14 -17) . Despite the established role of natural IgM in the pathogenesis of intestinal I/R-induced injury, regulatory mechanisms underlying the production of natural IgM are inadequately studied.
Natural IgM is spontaneously secreted by B1 B cells (18 -20) . B1 B cells can be further subdivided into B1a (CD5 ϩ ) and B1b (CD5 Ϫ ) (21) . Although still debatable, it has been demonstrated that B1a cells outside of the peritoneal cavity produce the majority of the natural IgM in naïve mice independent of T cells (18, 22, 23) , whereas B1b cells are responsible for T-independent IgM memory response (24) but are not a major source of natural IgM. How these natural IgM-producing B1a cells are regulated are also poorly understood despite the findings that antigen specificity and B cell receptor (BCR) signaling strength are critical factors in B1a cell development because deletion of BCR co-stimulatory molecules such as CD19 results in a massive reduction of B1a numbers, whereas deletion of negative regulators of BCR signaling such as Siglec-G leads to a vast increase in B1a cell population (25, 26) .
CD6 is a cell surface glycoprotein receptor originally discovered as a marker of T cells and was found present on a subset of human B cells (27, 28) . The precise function of CD6 in T cells is still uncertain. Previous studies suggested that CD6 is a costimulatory molecule that can synergize with the T cell receptor to enhance and/or inhibit T cell activation (29 -32) . Compared with the undefined role of CD6 on T cells, its role in B cells is even less clear. There has been only one report providing in vitro evidence, suggesting that CD6 could regulate apoptosis of chronic lymphocytic leukemia B cells (33) . The distribution of CD6 on murine B cells, whether it has any role in natural IgM production and in the development of intestinal I/R induced injury is completely unknown.
In this study, using WT and CD6 Ϫ/Ϫ mice, we studied the potential role of CD6 in regulating intestinal I/R-induced injury by comparing mucosal histopathology, local IL-6 production, and serum IgM titers. We explored the underlying mechanism by examining the distribution, regulation, and effect of CD6 on B1a cells. Our results showed the first evidence that CD6 is expressed on mouse B1a B cells and that CD6 regulates intestinal I/R-induced injury by modulating natural IgM-producing B1a cell self-renewal.
Results

CD6 Ϫ/Ϫ Mice Are Protected from Intestinal I/R-induced
Injury-To explore whether CD6 has any role in the gut epithelial barrier breaching and mucosal damage after I/R, we induced intestinal I/R-induced injury in sex-and age-matched WT and CD6 Ϫ/Ϫ mice following previously published protocol (10) and compared the clinical scores of the jejunum as well as local levels of IL-6 in these intestinal segments. We found that CD6 Ϫ/Ϫ mice showed marked increased epithelial cell layer integrity within the intestinal villi ( Fig. 1B ) with 3.5-fold lower tissue damage in the intestine after I/R than WT as quantified by clinical scores assigned in a blinded fashion by a pathologist (Fig. 1A ). In correlation with these histopathological analysis results in the CD6 Ϫ/Ϫ mice after intestinal I/R, ELISA analyses of the jejunum tissue lysate also found 22-fold lower levels of IL-6 than those in WT mice (Fig. 1C) . Thus, the severity of intestinal I/R-induced injury is significantly attenuated in the CD6 Ϫ/Ϫ mice, demonstrating a previously unknown role of CD6 in this pathological condition.
Pathogenic Natural IgMs Are Integrally Involved-It has been previously reported that natural IgM plays a critical role in inducing mucosal damage in this model of intestinal I/R-induced injury (10) . To understand the mechanism by which deficiency of CD6 protected mice from intestinal I/R-induced injury, we measured serum levels of total IgM in the serum of naïve WT and CD6 Ϫ/Ϫ mice. We found that although the titers of total IgG in the serum were similar between WT and CD6 Ϫ/Ϫ mice ( Fig. 2A ), the titers of natural IgM were reduced 1.9-fold in the CD6 Ϫ/Ϫ mice compared with WT mice (Fig. 2B ). Because natural IgM is reported to be polyreactive and only the pathogenic natural IgMs, e.g. anti-phosphorylcholine (PC) IgM and anti-annexin IV IgM, are critical in initiating intestinal I/Rinduced injury (12, 34) , we specifically measured titers of these pathogenic IgMs in the WT and CD6 Ϫ/Ϫ mice that were used in the I/R studies and found a 1.2-and 1.4-fold reduction of annexin IV-and PC-specific IgM titers, respectively, in the sera of CD6 Ϫ/Ϫ mice (Fig. 2 , C and D). To determine that reduced titers of pathogenic natural IgMs protected CD6 Ϫ/Ϫ mice from I/R-induced injury, we reconstituted IgM in the CD6 Ϫ/Ϫ mice by tail vein i.v. injection of IgMs purified from naïve WT mice before I/R procedures. We found that reconstitution restored the titers of the PC and annexin V-reactive IgMs in the CD6 Ϫ/Ϫ mice to those in the WT mice ( Fig. 2 , C and D) and that these reconstituted CD6 Ϫ/Ϫ mice showed increased local inflammation after I/R ( Fig. 2E ).
CD6 Is Selectively Expressed on B1 Cells outside the Bone Marrow and Peritoneal Cavity-The above-described results suggest that CD6 could have a previously unknown role in regulating B1a cells, which are the source of natural IgM. To test this, we first examined the expression of CD6 on all B cells and then focused on the B1a cells. We found that CD6 is not expressed on splenic B2 cells (specifically marginal and follicu-lar B cells) either constitutively ( Fig. 3A ) or after in vitro activation ( Fig. 3B ). Interestingly, using B1 cells from CD6 Ϫ/Ϫ mice as controls, we found that CD6 is expressed on B1 cells in the spleen ( Fig. 2A ). Among the B1 cell subsets in the spleen, neonatal liver, and peripheral blood, we found that the expression of CD6 was highly expressed on B1a cells compared with B1b cells. The full flow gating strategy for B1 B cells in the spleen, neonatal liver, peripheral blood, peritoneal cavity, and bone marrow are shown in supplemental Fig. 1 , A-D, and Fig. 2B , respectively).
Peritoneal B1a Cells Gain CD6 Expression outside the Peritoneal Cavity-Previous studies showed that B1a cells homeostatically migrate back and forth between the peritoneal cavity and the spleen (35, 36) . To explore the mechanism by which CD6 is not present on B1a cells in the peritoneal cavity, we tested whether these B1a cells will gain the expression of CD6 after they move out the peritoneal cavity. To do this we first examined the expression of CD6 on "migrant" peritoneal B1a cells (CD19 ϩ CD5 ϩ CD11b ϩ ) and found that CD6 is expressed on these migrant peritoneal B1a cells in the spleen (Fig. 5A ). To further confirm this result, we isolated peritoneal cells from WT mice, labeled them with carboxyfluorescein succinimidyl ester (CFSE), then injected them i.p. into naïve CD6 Ϫ/Ϫ recipient mice. To induce the adoptively transferred B1a cells to migrate out of the peritoneal cavity, we injected the recipient mice with LPS i.p. immediately after (35) . At 72 h, we analyzed CD6 expression on the CFSE ϩ peritoneal cells in the CD6 Ϫ/Ϫ recipient mice and found that these adoptively transferred peritoneal B1a cells gained CD6 expression in the spleen ( Fig. 5B ), suggesting that CD6 expression is induced on peritoneal B1a cells after they exited the peritoneal environment.
The B1 Cell Population Is Reduced in the Absence of CD6 in Select Tissue Compartments-Our data so far showed that 1) lack of CD6 protected mice from intestinal I/R injury, in which natural IgM plays a critical role in the pathogenesis, 2) blood levels of natural IgM were significantly reduced in the CD6 Ϫ/Ϫ mice, and 3) CD6 is expressed on B1 cells outside of the peritoneal cavity and bone marrow, which are one of the major sources of natural IgM. To determine why deficiency of CD6 leads to reduce IgM production, we compared the B1a cell population in the neonatal liver, peripheral blood, and spleen of WT and CD6 Ϫ/Ϫ mice by flow cytometry. We found a 4-and 2.5-fold reduction in the B1a cells frequency and absolute numbers in the CD6 Ϫ/Ϫ mice neonatal liver, respectively (Fig. 6A ). The decrease of the B1a cell population in the CD6 Ϫ/Ϫ neonatal liver was compensated with a 1.7-and 2.9-fold increase in the B1b cell frequency and absolute numbers as anticipated ( Fig.  6A , Table 1 ). In the peripheral blood, the frequency of B1a cells was decreased by 1.5-fold in the CD6 Ϫ/Ϫ mice ( Fig. 6B , Table 1 ). The frequency of B1b cells in the peripheral blood was increased by 1.4-fold in the CD6 Ϫ/Ϫ mice ( Fig. 6B , Table 1 ).
In the spleen we found a 2-and 2.5-fold decrease in the frequency and absolute numbers of B1a cells in the CD6 Ϫ/Ϫ mice ( Fig. 6C , Table 1 ). In the bone marrow, we found no significant difference in the frequency and absolute numbers of B1 cells (supplemental Fig. 2C and Table 2 ). In the peritoneal cavity we made some interesting observations. We found a 1.2-and 1.6fold reduction in the B1 cell frequency and absolute numbers,ϩ respectively, in the CD6 Ϫ/Ϫ mice. Upon further analysis of the B1 cell subsets, we found a 1.8-fold increase in the B1a cell frequency in the CD6 Ϫ/Ϫ mice. Although there was a 1.3-fold increase in the total B1a cell numbers in the CD6 Ϫ/Ϫ , there was no significant difference compared with WT mice. Additionally, in the CD6 Ϫ/Ϫ peritoneal cavity we found a 1.2-and 1.7fold compensatory reduction in the B1b cell frequency and absolute numbers, respectively (supplemental Fig. 2D and Table 2 ). Together, these data indicate that CD6 is required to maintain a normal B1a cell population in these tissues, and the significantly reduced population of B1a cells in CD6 Ϫ/Ϫ mice could explain the markedly reduced blood IgM levels that we found in the above experiments.
Reduced B1a Cell Population in CD6 Ϫ/Ϫ Mice Is Due to Impaired B1a Cell Self-renewal-We then explored the possible mechanism by which the absence of CD6 resulted in the reduced numbers of B1a cells in the CD6 Ϫ/Ϫ mice. The B1a cell population is maintained by their unique ability to undergo self-renewal (37, 38) . In asplenic mice, the B1a cell population is significantly reduced in multiple tissue compartments, highlighting the importance of the spleen in B1a self-renewal (39) .
To determine if the reduced B1a cell population in the CD6 Ϫ/Ϫ mice is caused by their impaired ability to undergo self-renewal, we measured B1a cell proliferation between WT and CD6 Ϫ/Ϫ mice using a BrdU incorporation assay. Incorporation of BrdU by splenic B1a cells was reduced by 1.5-fold in the CD6 Ϫ/Ϫ mice ( Fig. 7A ). To determine if CD6 plays an intrinsic role in B1a cell proliferation, we also assessed BrdU incorporation of peritoneal B1a and bone marrow B1 cells that do not express CD6. We found no significant difference in either peritoneal B1a (supplemental Fig. 3A) or bone marrow B1 cell proliferation between WT and CD6 Ϫ/Ϫ mice (supplemental Fig. 3B ). In addition to impaired self-renewal, reduced B1a cell population in CD6 Ϫ/Ϫ mice may result from enhanced apoptosis of these cells given that CD6 has been implicated in the survival of B1aderived B-CLL cells (33) . We compared the frequency of apo- 
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ptotic splenic B1a cells in WT and CD6 Ϫ/Ϫ mice before and after LPS stimulation by annexin V staining. There were no differences in splenic B1a apoptosis basally or upon activation (Fig. 7B) . These data indicate that the reduction of B1a cell population in the CD6 Ϫ/Ϫ mice is due to impaired self-renewal of B1a cells and not enhanced apoptosis.
Elevated basal Erk phosphorylation is one of the hallmark features of naive B1a cells (40) . To determine whether the reduced splenic B1a cell self-renewal in CD6 Ϫ/Ϫ mice is associated with impaired Erk phosphorylation, we compared the basal Erk phosphorylation of WT and CD6 Ϫ/Ϫ splenic B1a cells. CD6 Ϫ/Ϫ splenic B1a cells displayed a slight increase in basal Erk phosphorylation compared with WT; however, the difference was not significant (Fig. 7C ). We also analyzed the expression levels of NFATc1, a transcription factor that has been shown to be important for B1a cell development/survival (41) . A slightly elevated but insignificant increase in NFATc1 expression levels was detected in CD6 Ϫ/Ϫ splenic B1a cells (Fig.  7D ). Taken together, these data suggest that reduced self-renewal of CD6-deficient B1a cells is independent of impaired Erk signaling and NFATc1 activity.
Discussion
In this report we studied CD6 Ϫ/Ϫ mice in a model of intestinal I/R-induced injury, a devastating and likely lethal pathological condition. We found that CD6 Ϫ/Ϫ mice were protected from intestinal I/R-induced injury as shown by significantly attenuated histopathology of the intestine and reduced levels of local IL-6. In mechanistic studies we found that total annexin IV, and PC-specific IgM titers were reduced in the CD6 Ϫ/Ϫ mice and that reconstitution of CD6 Ϫ/Ϫ mice with IgM from naïve WT mice significantly restored intestinal I/R-induced inflammation. In addition, we demonstrated that CD6 was selectively expressed on natural antibody producing-B1 cell outside of the peritoneal cavity and bone marrow. Finally, we found that CD6-expressing B1 cells were significantly reduced in select tissue compartments in the CD6 Ϫ/Ϫ mice in association with reduced B1a cell proliferation.
Intestinal I/R-induced injury is a condition frequently associated with high morbidity and mortality in patients with trauma and surgeries, especially small intestine transplantation (1) . The unexpected results that CD6 Ϫ/Ϫ mice were protected in the intestinal I/R-mediated injury demonstrated a previously unknown role of CD6 in the pathogenesis of this condition. CD6 was originally identified as a marker for T cells and has been associated with multiple autoimmune diseases including rheumatoid arthritis and psoriasis (42, 43) . Quantitative proteomics analysis of signalosome dynamics in T cells identifies CD6 as a Lat adaptor-independent TCR signaling hub, suggesting that CD6 modulates TCR signaling (44) . A recent study using CD6-deficient mice found exacerbated collagen-induced arthritis in the CD6 Ϫ/Ϫ mice (45), a surprising result because anti-CD6 mAbs showed efficacy in treating patients with rheumatoid arthritis (46) and psoriasis (47) . Compared with the debatable role of CD6 on T cells, information on the potential role of CD6 on B cells is even more limited. So far, it has only been reported that a proportion of blood CD6 ϩ B cells is reduced in primary Sjögren's syndrome patients (28) and that CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis (49) . Our results that CD6 deficiency led to impaired B1a cell self-renewal, reduced B1a cell population, and natural IgM titers in the blood showed a new role for CD6 in regulating B cells for the first time.
The discovery that CD6 Ϫ/Ϫ mice have reduced titers of pathogenic natural IgM and are protected from intestinal I/R-induced injury is consistent with previous reports that natural IgM is critical in I/R-induced injury (10, 13) . RAG1 Ϫ/Ϫ mice, which do not have any antibodies, are highly resistant to intestinal I/R-induced injury but become susceptible again after reconstitution with purified serum IgM from naïve WT mice or an IgM mAb alone (clone B4), which specifically recognizes annexin IV (15) . In addition to annexin IV, natural IgM reactive to PC has also been implicated in the pathogenesis of intestinal I/R-induced injury (12, 15, 50) . Consistent with these previous reports, we found that natural IgM specific for PC and annexin IV were significantly reduced in the blood of CD6 Ϫ/Ϫ mice compared with WT mice in association with decreased intestinal I/R-induced injury and that supplementing IgMs isolated from naïve WT mice into CD6 Ϫ/Ϫ mice increased titers of both PC-and annexin IV-specific IgMs, leading to exacerbated intestinal inflammation after I/R. Beside nature IgM, several studies have implicated a role for T cells in this acute inflammatory model (51) (52) (53) . The recent The absence of CD6 expression on mature B2 cells in mice was an interesting finding because CD6 is reported to be present on mature B2 cells in humans (28) . CD6 is closely related to the lymphocyte receptor CD5 (54) . These two genes are immediately adjacent to each other and are highly homologous members of the group B scavenger receptor cysteine-rich (SRCR) superfamily of protein receptors, previously reported to be coexpressed on the same cells (54, 55) . In mouse B cells, CD5 is not expressed on naïve B2 cells; however anti-IgM stimulation of B2 cells induces CD5 expression (56) . In our studies, in vitro stimulation of mouse B2 cells did not induce appreciable expression of CD6. These findings suggest that although CD5 and CD6 are closely related, the mechanism regulating their expression in mouse B cells is distinct and different from T cells wherein expression of CD5 and CD6 appears coordinated. The discovery that CD6 is differentially expressed on mouse B1 cells adds CD6 to a list of unique markers that are differentially expressed between peritoneal and splenic B1 cells (57) . This finding also indicates that bone marrow B1 and splenic B1 cells may also express differential markers. Differential expression of CD6 raises the possibilities that CD6 ϩ B1 and CD6 Ϫ B1 cells may arise from two distinct B1 cell lineages and/or that CD6 expression is heavily influenced by the local microenvironment. The expression of CD6 on migrant peritoneal B1a cells in the spleen and the discovery that WT peritoneal B1a cells acquire CD6 expression in the spleen of CD6 Ϫ/Ϫ recipient mice after adoptive-transfer strongly supports the notion that the microenvironment greatly influences expression of CD6 and drives phenotypic differences in B1a cells (58, 59) .
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The deletion of certain BCR signaling positive regulators results in the massive reduction of B1a cells (37) . Reduction of the B1a cell population outside the bone marrow and peritoneal cavity in the CD6 Ϫ/Ϫ mice suggest that CD6 is a positive regulator of BCR signaling. In T cells, CD6 can initiate its own signaling hub and tune overall T cell receptor signaling threshold thru its ability to recruit signaling molecules such as SLP-76 and Vav1 (44) . Given that enhanced BCR signaling is one of the critical factors in B1a development, our data support the hypothesis that CD6 signaling contributes to the overall BCR signaling threshold that shapes the B1a development process.
The B1 cells in the bone marrow and peritoneal cavity do not express CD6. As anticipated, the deficiency of CD6 did not alter the B1 cell population in the bone marrow. In contrast, we found reduced B1 cells in the peritoneal cavity of CD6 Ϫ/Ϫ mice. These findings are consistent with the recent study indicating that serum IgM-deficient mice display reduced B1 cell population in the peritoneal cavity and normal B1 cell population in the bone marrow (48) . These serum IgM-deficient mice also harbor large amounts of anergic CD5 ϩ B cells, which potentially could account for the elevated CD5 ϩ B1a cells population in the peritoneal cavity of CD6 Ϫ/Ϫ mice. The discovery that the B1 cell population in the CD6 Ϫ/Ϫ mice bone marrow are not altered despite altered B1 cell population in the peripheral tissue suggest a potential defect in the renewal/proliferation rather than in the development of B1 cells. We assessed the proliferation of B1a cells and discovered that CD6-deficient mice displayed reduced proliferation compared with WT. Specifically, the defect was only found in CD6-expressing B1a cells. These data suggest that CD6 plays an intrinsic role in B1a cell self-renewal.
Thus, our working model is that CD6 deficiency impairs the self-renewal of natural IgM-secreting B1a cells, therefore reducing the B1a cell population. The reduction of the B1a cell population results in reduced pathogenic natural antibodies (annexin IV and PC-specific IgM) in the blood. Reduced recognition of ischemic neo-antigens by natural IgM subsets in the CD6 Ϫ/Ϫ mice led to impaired inflammatory responses such as IL-6 production during reperfusion of the intestine, and, consequently, attenuated mucosal damage. This study provides new insight into the role of CD6 in the inflammatory process 
Materials and Methods
Mice-CD6 Ϫ/Ϫ mice were developed by manipulating ES cells using a conventional homologous recombination strategy and blastocyst injection of the identified target ES cells. The resultant CD6 Ϫ/Ϫ mice were bred onto the DBA/1 background by Ͼ12 generations of backcrossing. PCR and Southern blot assays verified the deletion of the targeted loci, and flow cytometry analysis of CD6 protein on T cells confirmed the deficiency of CD6 in the CD6 Ϫ/Ϫ mice (details will be described in another report). All mice were maintained in the animal facility at the Cleveland Clinic, and all animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic.
Mouse Intestinal I/R Model-The intestine ischemia and reperfusion was performed on mice at 8 -12 weeks of age. Surgical instruments were sterilized by autoclave before surgery. The mice were anesthetized with 4% isoflurane inhalation for induction and 0.5% for maintenance of anesthesia using an approved anesthetic gas machine. The mouse abdomen skin was cleaned and entered via a midline laparotomy incision. The superior mesenteric artery was identified and isolated, and then the VASCU-STATT Plus bulldog clamp (Scanlan, Saint Paul, MN) was utilized to perform the vascular exclusion for 30 min. A heating pad was applied to keep the mouse body temperature around 37°C. After 30 min of mesenteric ischemia phase, the clamp was removed, and the midline laparotomy incisions were closed with 4 -0 silk suture; the intestine was reperfused for 3 h before the tissue (jejunum) was harvested. For some experiments, CD6 Ϫ/Ϫ mice were reconstituted with 100 g of mouse IgM (Rockland Immunochemicals Inc., Limerick, PA) mouse intravenously 30 min before the start of the intestinal ischemia-surgery.
Local IL-6 Assay-The jejunum tissue was mechanically homogenized in Nonidet P-40 lysis buffer (Invitrogen) containing a tablet of protease inhibitors (Roche Applied Science). The homogenized tissue was incubated on ice for 30 min with brief vortexing every 5 min. Tissue lysates were centrifuged at 13,000 rpm for 30 min at 4°C, the pellets were discarded, and protein concentration of the supernatant was measured using the Pierce BCA Protein Assay kit. For the detection of IL-6 levels in the supernatant, 96-well high binding plates were coated with 2 g/ml rat anti-mouse IL-6 (BioLegend) diluted in 1ϫ PBS. Protein lysates were diluted 1/20 and loaded onto the coated ELISA plate. Bound IL-6 was detection using biotin anti-mouse IL-6 (BioLegend) and subsequently using avidin-HRP (BioLegend). The ELISA color reaction was initiated using tetramethylbenzidine (TMB) substrate (Thermo Scientific). 2 M H 2 SO 4 was used to stop the TMB reaction, and absorbance at 450 nm was measured. IL-6 concentration was normalized to the starting initial protein concentration.
Histology and Injury Scoring-Histopathological examination and tissue injury score was performed in a blinded manner by a pathologist on 4-m-thick paraffin-embedded sections stained with hematoxylin and eosin. Digital images were cap-tured with a Leica-DM5500 B microscope camera (Buffalo Grove, IL) and analyzed with Image-Pro software (Media Cybernectics, Silver Spring, MD).
Flow Cytometry-Single-cell suspensions of spleen, peritoneal lavage from adult mice, or day-7 old neonatal liver were incubated for 10 min on ice with anti-mouse CD16/32 Fc blocking antibody (BioLegend). After Fc blocking, cells were incubated with varying combinations of the following antibodies: anti-CD19, anti-CD43, anti-CD5, anti-CD6 clone 34 (prepared in the laboratory), anti-CD11b, anti-CD80, anti-CD86, anti-IgM, anti-CD23, and anti-CD21. All antibodies were purchased from BioLegend. Cells were stained in FACS buffer, and expression of cell surface markers was acquired on both BD LSR-Fortessa and FACSCalibur flow cytometer. Acquired flow cytometer data were analyzed using the Flowjo software. For splenic B1a intracellular staining, splenocytes from WT and CD6 Ϫ/Ϫ mice were first incubated with antibodies to CD19, CD43, and CD5 as previously described. After cell surface staining, the cells were fixed and permeabilized using the BD Biosciences permeabilization kit according to the manufacturer's instruction. The permeabilized splenocytes were incubated with anti-pERK (T204/Y202) (eBioscience), NFATc1 (Bio-Legend), mouse IgG1 isotype control (BD Bioscience), or rat isotype control antibody (BioLegend).
Splenic B2 Cells in Vitro Stimulation-Single-cell suspensions of spleen were plated at a density of 10 6 cells/ml in a 96-well plate. For the detection of CD6 expression on splenic B2 cells, splenocytes from WT and CD6 Ϫ/Ϫ mice were harvested after 72 h in vitro stimulation with 10 g/ml goat F(abЈ) 2 anti-IgM and IL-4 (1000 units/ml) (Peprotech) or 5 g/ml of LPS (Sigma), and CD6 expression was analyzed on activated CD19 ϩ (B2 cells) by flow cytometry.
Peritoneal B1a Cells Migration to the Spleen-Peritoneal cells were isolated from WT and CD6 Ϫ/Ϫ mice by peritoneal lavage. 5 ϫ 10 6 cells were labeled in vitro with CFSE (Invitrogen) and transferred into the peritoneal cavity of CD6 Ϫ/Ϫ recipient mice. Two hours post-adoptive transfer, 5 g of LPS (Sigma) was also administered into the peritoneal cavity. After 72 h, splenocytes were isolated, and CD6 expression was analyzed on CFSE-positive cells in addition to gating on CD19 and CD5 double-positive cells (CFSE ϩ CD19 ϩ CD5 ϩ ).
BrdU Incorporation-WT and CD6 Ϫ/Ϫ mice were intraperitoneally injected with 500 l of BrdU (BD Biosciences) at a diluted concentration of 1 mg/ml every other day for 7 days. At the end of the study, splenocytes, bone marrow, and peritoneal cavity cells were isolated and stained with various antibodies (CD19, CD43, and CD5; CD19 and CD43; B220, CD11b, and CD5), respectively. After cell surface staining on ice, the cells were fixed and permeabilized. After permeabilization, the cells were intracellular stained with FITC-labeled anti-BrdU antibody (BD Biosciences) and analyzed by flow cytometry.
ELISA-For the detection of total IgG or IgM serum levels, 96-well high binding plates (Greiner Bio-One) were coated with 0.34 g/ml rabbit anti-mouse IgMϩIgG (HϩL) (Jackson ImmunoResearch). Serum samples were diluted 1/1000. Bound antibodies were detected using either goat anti-mouse IgM HRP (Southern Biotech) or rat anti-mouse IgG-HRP (Southern Biotech). For the detection of PC-specific IgM, plates were CD6 Promotes Intestinal Ischemia/Reperfusion-induced Injury coated with 10 g/ml PC-BSA (Biosearch Technologies). Serum samples were also diluted 1/1000, and bound PC-specific IgM antibodies were detected using goat anti-mouse IgM-HRP. For the detection of annexin IV-specific IgM, plates were coated with 1 g/ml recombinant mouse annexin IV (LSBio). Serum samples were diluted 1/50, and bound annexin IV-specific IgM was detected using goat anti-mouse IgM-HRP. The ELISA color reaction was initiated using TMB substrate (Thermo Scientific, MA). 2 M H 2 SO 4 was used to stop the TMB reaction, and absorbance at 450 nm was measured.
Statistical Analysis-Data were compared by unpaired t test or paired t test using the GraphPad Prism software with a twotailed Student's t test of equal variance. The difference between the groups was considered significant at p Ͻ 0.05. 
